Mutations were most commonly identified in epigenetic modifier genes such as ASXL1, DNMT3A, and TET2. Two retrospective studies suggested an inferior response to TKI of CML patients harboring mutations of epigenetic regulator genes [7, 9]. The gene discussed is DNMT3A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.